0
Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

ÁßÁõ ³ú ¼Õ»óȯÀÚ¸¦ À§ÇÑ ¹ÙºñÆ©·¹ÀÌÆ® È¥¼ö¿ä¹ýÀÇ Ç¥ÁØÀÓ»óÁöħ(Critical Pathway) °³¹ß

Development of a Critical Pathway of Barbiturate Coma Therapy in the Management for Severe Brain Damage

°£È£ÇàÁ¤ÇÐȸÁö 2010³â 16±Ç 1È£ p.59 ~ 72
KMID : 0614820100160010059
±èÁ¤¼÷ ( Kim Jung-Sook ) - »ï¼º¼­¿ïº´¿ø °£È£ºÎ

Abstract

Purpose: This study is a descriptive research to analyze prognostic factors of barbiturate coma therapy (BCT) for severe brain damage patients, to develop a critical pathway (CP) based on the results of analysis and to examine the effect of its clinical application.

Method: We analyzed medical records of 76 patients who received BCT for more than three days between January 1999 to July 2005. Based on the results of the analysis, we developed a CP and applied it to 12 people during August-December of 2005.

Result: By application of BCT CP, the mortality rate decreased from 31.6% to 16.7%. It was found that the period of staying at ICU and total period of hospitalization were shortened by 2.78 (13.9%) days and 16.43 (29.4%) days, respectively. The Glasgow coma scale of the recovery group by CP application was 9.03 (4.64) at 72 hours post of BCT and 14.28 (1.82) at discharge from hospital, and DRS was 6.62 (6.38) points.

Conclusion: By verifying clinical validity of the suggested CP, we believe that we have obtained visible effects standardizing the treatment pathway of BCT for brain damage patients.
KeyWords
¹ÙºñÆ©·¹ÀÌÆ® È¥¼ö¿ä¹ý, Ç¥ÁØÀÓ»óÁöħ, ³ú ¼Õ»ó
Barbiturate coma therapy, Critical pathway, Brain injury
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
  
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed